NEW YORK — Progentec Diagnostics said on Thursday that it has secured a $225,000 grant from the National Institutes of Allergy and Infectious Diseases to advance blood biomarker-based laboratory tests for systemic lupus erythematosus.
With the Phase I Small Business Innovation Research grant, the Oklahoma City-based company said it aims to validate the prognostic value of the lupus biomarkers and analysis methods it has developed, which include a protein biomarker platform and assay for predicting disease flares.
"We anticipate that the tests in development by Progentec will support clinicians in selecting optimal treatment plans, adjusting medication dosing, and measuring outcomes for lupus patients," Progentec CEO Mohan Purushothaman said in a statement.
Late last year, Progentec raised $1.25 million in investment funding and acquired health management platform LupusCorner.